• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Ligand Pharmaceuticals Inc

+ Add to Watchlist

LGDN:GR

36.682 EUR 0.484 1.30%

As of 03:00:32 ET on 09/23/2014.

Snapshot for Ligand Pharmaceuticals Inc (LGDN)

Open: 37.040 Day's Range: 36.682 - 37.040 Volume: 0
Previous Close: 37.166 52wk Range: 29.806 - 58.731 1-Yr Rtn: +14.46%

Stock Chart for LGDN

No chart data available.
  • LGDN:GR 36.682
  • 1D
  • 1M
  • 1Y
37.166
Interactive LGDN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for LGDN

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) 38.5326
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) 1.2230
Est. PEG Ratio -
Market Cap (M EUR) 762.28
Shares Outstanding (M) 20.78
30 Day Average Volume 16
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 15.0000
Dividend Ex-Date 04/03/2007
5 Year Dividend Growth -
Next Earnings Announcement 10/30/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for LGDN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for LGDN

Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.

John L HigginsPresident/CEOMatthew W Foehr "Matt"Exec VP/COO
Charles S BerkmanVP/Secretary/General CounselNishan De SilvaVP:Finance & Strategy/CFO
More Company Profile & Key Executives for LGDN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil